Floatz logo

Lapatinib

BRMS1

Latin American Cooperative Oncology GroupSmall moleculePhase 2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the BRMS1 cohort.

Asset / SponsorPhaseRating
Vinorelbine
Latin American Cooperative Oncology Group
Phase 2B
Capecitabine
Latin American Cooperative Oncology Group
Phase 2B

Same molecule, other indications

Lapatinib is also rated in:

breast cancerDormant
BBB
Indicative ·
76 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
male breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →